Imatinib Mesylate API, Grade Standard: USP

Imatinib Mesylate is an Active Pharmaceutical Ingredient (API) used as a targeted tyrosine kinase inhibitor (TKI) for treating chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other blood disorders. It functions by inhibiting BCR-ABL tyrosine kinase, c-Kit, and PDGFR, inducing apoptosis in cancer cells. It is typically supplied as a white to off-white powder, with high solubility in the mesylate salt form, and is used to manufacture oral tablets and capsules. About the Company GST Registration Date: 2024 Legal Status of Firm: Partnership Number of Employees: 11 To 25 People Annual Turnover: 1.5 - 5 Cr company-description: Gathi Lifesciences is a dynamic and growing partnership firm established in 2024 in the thriving pharmaceutical hub of Telangana, India. We specialize in the trading and distribution of high-quality API Intermediates-key raw materials used in the production of pharmaceutical drugs. Our operations are rooted in the commitment to providing reliable, cost-effective solutions to our clients in the pharmaceutical, biotech, and healthcare industries. As a trusted partner, Gathi Lifesciences ensures that all our products meet the highest standards of quality and regulatory compliance. Our firm leverages cutting-edge logistics, robust supply chain management, and a deep understanding of global markets to deliver timely and efficient services. Positioned strategically in Telangana, we are at the heart of one of India's largest pharmaceutical manufacturing ecosystems, allowing us to serve both domestic and international clients with precision and care.